BDSI Prices Public Offering of 4.4 Million Shares
2005年9月30日 - 9:04PM
ビジネスワイヤ(英語)
BioDelivery Sciences International, Inc. (NASDAQ: BDSI, BDSIW), a
specialty pharmaceutical company, announced today that it has
priced a public offering of 4,400,000 shares of its common stock
which is anticipated to raise gross proceeds of $8,800,000 million
for the company. The public price per share for the offering is
$2.00. The offering is being underwritten by Ferris, Baker Watts
Incorporated, Maxim Group LLC and GunnAllen Financial, Inc. The
underwriters have been granted an option to purchase up to an
additional 660,000 shares of common stock from the company to cover
over-allotments. If the over allotment option is exercised, of
which no assurances can be given, the additional shares will also
be sold at $2.00 per share and will result in additional gross
proceeds to BDSI of up to $1,320,000. This communication shall not
constitute an offer to sell or a solicitation of an offer to buy,
nor shall there be any sale of any securities in any state or
jurisdiction in which such offer, solicitation or sale would be
unlawful. BioDelivery Sciences International, Inc. is a specialty
biopharmaceutical company that is exploiting its licensed and
patented drug delivery technologies to develop and commercialize,
either on its own or in partnerships with third parties,
clinically-significant new formulations of proven therapeutics
targeted at "acute" treatment opportunities such as pain, anxiety,
nausea and vomiting and infections. The company's drug delivery
technologies include: (i) the patented Bioral(R) nanocochleate
technology, designed for a potentially broad base of applications,
and (ii) the patented BEMA(TM) (transmucosal or mouth) drug
delivery technology. The company's headquarters are located in
Morrisville, North Carolina and its principal laboratory is located
in Newark, New Jersey. Note: Except for the historical information
contained herein, this press release contains, among other things,
certain forward-looking statements, within the meaning of the
Private Securities Litigation Reform Act of 1995, that involve
risks and uncertainties. Such statement may include, without
limitation, statements with respect to the Company's plans,
objectives, expectations and intentions and other statements
identified by words such as "may", "could", "would", "should",
"believes", "expects", "anticipates", "estimates", "intends",
"plans" or similar expressions. These statements are based upon the
current beliefs and expectations of the Company's management and
are subject to significant risks and uncertainties, including those
detailed in the Company's filings with the Securities and Exchange
Commission. Actual results may differ from those set forth in the
forward-looking statements. These forward-looking statements
involve certain risks and uncertainties that are subject to change
based on various factors (many of which are beyond the Company's
control). L.G. Zangani, LLC provides financial public relations
service to the Company. As such L.G. Zangani, LLC and/or its
officers, agents and employees, receives remuneration for public
relations and or other services in the form of monies, capital
stock in the Company, warrants or options to purchase capital in
the Company.
Biodelivery Sciences International (MM) (NASDAQ:BDSIW)
過去 株価チャート
から 8 2024 まで 9 2024
Biodelivery Sciences International (MM) (NASDAQ:BDSIW)
過去 株価チャート
から 9 2023 まで 9 2024